Abstract: A new process for preparing s-triazolo[5,1-a]-isoquinoline derivatives of the formula ##STR1## wherein A represents the group --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--; R is selected from hydrogen, amino, lower alkylamino, di-lower alkylamino, acylamino, diacylamino, ureido, thioureido, carbethoxythioureido, benzoylthioureido, sulfhydryl, lower alkyl, trifluoromethyl, phenyl, substituted phenyl, pyridyl, methylpyridyl and dimethylpyridyl; and R.sub.1 and R.sub.2 each independently represents hydrogen or lower alkoxy; by condensation of a 2-amino-3,4-dihydro-1(2H)-isoquinolinone with an imidolyl, cyanamide, cyanic or thiocyanic derivative.New compounds of the formula I wherein A represents the group --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, R has the same meaning as above with the exclusion of hydrogen, methyl, phenyl, and trifluoromethyl, R.sub.1 and R.sub.2 have the same meaning as above, with the proviso that when A represents the group --CH.dbd.CH--, R cannot be tolyl or pyridyl.

Abstract: 5-[1-HYDROXY-2-(HETEROCYCLIC AMINO)]ETHYL-8-HYDROXY-3,4-DIHYDROCARBOSTYRIL DERIVATIVES REPRESENTED BY THE FORMULA (I) wherein A, when taken together with the nitrogen atom to which it is attached, forms a 6-membered substituted or unsubstituted heterocyclic ring containing 1 or 2 nitrogen, or oxygen atoms as hetero atoms, the pharmaceutically acceptable acid addition salts thereof, and a process for preparing the above compounds.

Abstract: The invention relates to 3,4-dihydro-2H-isoquinolin-1-thiones and a process for preparing them.The compounds have an antiarrhythmic activity and are suitable for treating disturbance of the cardiac rhythm.

Abstract: The invention discloses 1,2,5,6-tetrahydro-4H-pyrrolo-(3,2,1-ij)quinolin-2-ones having pharmacological activity in animals and useful as CNS depressant agents. The compounds may be prepared by treating a haloacetyl derivative of 1,2,3,4-tetrahydroquinoline with a Friedel-Crafts catalyst. The haloacetyl derivative of 1,2,3,4-tetrahydroquinoline may be prepared by reacting 1,2,3,4-tetrahydroquinoline with a haloacetyl halide at a mole ratio of 2:1 in the presence of an inert, organic solvent.